FDA requires label warnings to prohibit sharing of multi-dose diabetes pen devices among patients.
FDA requires label warnings to prohibit sharing of multi-dose diabetes pen devices among patients. FDA Safety Communication. Silver Spring, MD: US Food and Drug Administration; February 25, 2015.
The practice of using multi-dose insulin pens, meant for single patient use only, among multiple patients has been linked to health care–associated infections. This announcement outlines federal labeling requirements to raise awareness of the risks associated with this practice to prevent misuse of the devices.